Veracyte: Diagnostics With Favorable Economics

Impact · against what's priced in

Veracyte shows strong fundamentals with double-digit growth and margin expansion in core tests, but the primary catalyst is the unguided upside from Prosigna and TrueMRD. This provides a revenue cushion and growth potential beyond the market's current 2026 expectations.

VCYT+0.60

No priced-in read yet

In context

Double-digit growth and margin expansion in Decipher and Afirma provide a strong baseline, while Prosigna and TrueMRD offer long-term upside not yet reflected in 2026 revenue guidance.

Read from the article alone

• growth stocks▲28%
• cash flow▲10%
• biotech
• VCYT
• diagnostics
• revenue guidance

Top 2 movers · tap to explore